Welcome! Here you can find resources for sites of care receiving and administering COVID-19 antibody infusions.
On April 16, 2021, the FDA revoked emergency use authorization for bamlanivimab monotherapy due to the increased prevalence of SARS-CoV-2 variants that are expected to be resistant to bamlanivimab administered alone. This change comes at the request of the manufacturer, Eli Lilly, due to the availability of more efficacious monoclonal antibody therapies, and is not related to any adverse events or safety issues. Bamlanivimab is still authorized for use when administered with etesevimab per the EUA. Infusion providers with remaining bamlanivimab inventory should contact AmerisourceBergen to order etesevimab to be paired with the remaining bamlanivimab. For more information, see the FDA’s Letter of Revocation, and Frequently Asked Questions on the Revocation of the Emergency Use Authorization for Bamlanivimab Administered Alone.
Drip rates for administering COVID-19 antibody infusions by gravity. (Updated 6-9-21)
Casirivimab and Imdevimab are supplied in multiple packaging configurations and have unique preparation requirements that may increase risk for medication errors.
Use this flowsheet to document infusion therapies and provide a detailed record to fax to the referring prescriber. The flowsheet also guides the clinician to adhere to administration and documentation requirements. (Updated 6-15-21)
Regeneron Casirivimab + Imdevimab Emergency Use Authorization (EUA) Guidebook
NICA collaborated with Regeneron to develop this playbook with in-depth information about Casirivimab + Imdevimab